{"id":"NCT03161093","sponsor":"Regeneron Pharmaceuticals","briefTitle":"A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip","officialTitle":"A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-17","primaryCompletion":"2019-09-09","completion":"2021-08-27","firstPosted":"2017-05-19","resultsPosted":"2022-11-14","lastUpdate":"2022-11-14"},"enrollment":3307,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis, Knee","Osteoarthritis, Hip"],"interventions":[{"type":"DRUG","name":"Fasinumab","otherNames":["REGN475"]},{"type":"DRUG","name":"Naproxen","otherNames":[]},{"type":"DRUG","name":"Fasinumab-matching placebo","otherNames":[]},{"type":"DRUG","name":"Naproxen-matching placebo","otherNames":[]}],"arms":[{"label":"Fasinumab dosing regimen 1","type":"EXPERIMENTAL"},{"label":"Fasinumab dosing regimen 2","type":"EXPERIMENTAL"},{"label":"Fasinumab-matching placebo and naproxen","type":"EXPERIMENTAL"},{"label":"Fasinumab-matching placebo and naproxen-matching placebo","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to evaluate the efficacy of fasinumab compared with placebo, when administered for up to 16 weeks in patients with pain due to osteoarthritis (OA) of the knee or hip.\n\nThe secondary objectives of the study are:\n\n1. To evaluate the efficacy of fasinumab compared with naproxen, when administered for up to 16 weeks in patients with pain due to OA of the knee or hip\n2. To evaluate the efficacy of fasinumab compared with placebo, when administered for up to 44 weeks in patients with pain due to OA of the knee or hip\n3. To assess the safety and tolerability of fasinumab compared with naproxen, when administered for up to 16 weeks in patients with pain due to OA of the knee or hip\n4. To assess the safety and tolerability of fasinumab compared with naproxen, when administered for up to 52 weeks in patients with pain due to OA of the knee or hip\n5. To assess the safety and tolerability of fasinumab compared with naproxen, when administered for up to 104 weeks in patients with pain due to OA of the knee or hip\n6. To evaluate the pharmacokinetic (PK) profile of fasinumab administered to patients with pain due to OA of the knee or hip for up to 52 weeks\n7. To evaluate the PK profile of fasimumab administered to patients with pain due to OA of the knee or hip for up to 104 weeks\n8. To evaluate the immunogenicity of fasinumab administered to patients with pain due to OA of the knee or hip for up to 52 weeks\n9. To evaluate the immunogenicity of fasinumab administered to patients with pain due to OA of the knee or hip for up to 104 weeks\n10. To evaluate the efficacy of fasinumab compared with naproxen, when administered for up to 44 weeks in patients with pain due to OA of the knee or hip","primaryOutcome":{"measure":"Change in the WOMAC Pain Subscale Scores From Baseline to Week 16 in Participants Treated With Fasinumab 1mg SC Q4W Compared With That of Participants Treated With Placebo","timeFrame":"Baseline to Week 16","effectByArm":[{"arm":"Placebo","deltaMin":-1.82,"sd":0.162},{"arm":"Fasinumab 1 mg SC Q4W","deltaMin":-2.49,"sd":0.098}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0002"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":139,"countries":["United States","Denmark","Germany","Hungary","Lithuania","Poland","Romania","Russia","South Africa","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":49,"n":352},"commonTop":["Arthralgia","Headache","Back pain","Nasopharyngitis","Upper respiratory tract infection"]}}